Products and Services
RSS
Biopharmaceutical Development: GPEx® Gene Product Expression Technology
Catalent Pharma Solutions
GPEx® technology uses a retrovector technology that ensures the stable transduction of targeted cells, approaching 100% efficiency. This level of efficiency eliminates the requirement for selectable markers — something conventional methods must use during selection and gene amplification.
Click Here To Download:
•Product Brochure: Biopharmaceutical Development: GPEx® Gene Product Expression Technology
•Product Brochure: Biopharmaceutical Development: GPEx® Gene Product Expression Technology
•Product Brochure: Biopharmaceutical Development: GPEx® Gene Product Expression Technology
GPEx technology uses a retrovector technology that ensures the stable transduction of targeted cells, approaching 100% efficiency. This level of efficiency eliminates the requirement for selectable markers—something conventional methods must use during selection and gene amplification.
Using GPEx technology, stably-transduced (selectable marker gene–free) cell lines are produced in less than five months. The technology can be applied to any mammalian cell line or used with in-house Master Cell Banked CHO parental cell line.
With favorable expression levels, expression stability and timelines to your product development cycle, GPEx-based cell lines can be ready to support all of your future manufacturing needs.
Click Here To Download:•Product Brochure: Biopharmaceutical Development: GPEx® Gene Product Expression Technology
